Tori Fairweather, a 24-year old Hodgkin’s lymphoma survivor of Puyallup, Wash., was initially worried about asking her oncologist about a second opinion for fear he’d feel “dissed.”
But when she broached the topic with him, he was actually supportive of the idea. “There was no pressure to make a decision. He wanted me to go with what was most comfortable for me,” she said. “I just thought that was wonderful, putting ego aside to treat me and to make sure I had the best care.”
Fairweather saw SCCA’s Dr. Stephen Smith for her second opinion and ended up transferring her care to him. She liked that Smith was a specialist in her type of cancer.
“It was validating because I knew that they were specifically working to cure lymphoma,” Fairweather said. “I just totally felt like I was No. 1. That was the best feeling, knowing that I was in good care.”
Doctors at SCCA end up giving a lot of second opinions, Gralow said, because they are specialists in their fields. Sometimes, other doctors are the ones asking her and her colleagues for their opinions.
“We have the luxury of being real specialists because we are academics,” Gralow said. “A lot of times, especially if they’re a private practice oncologist or a general surgeon, [other doctors] actually like to know what somebody who has the luxury of spending all their time on one disease would think about this.”
Dedicated cancer centers like SCCA also offer many clinical trial options not available at smaller or private practices, Gralow said. For some patients those trials might end up being their best treatment option.
Some patients end up transferring their care, as Fairweather and Kiggins did, but others go back to their original provider with more confidence, Gralow said. And some patients end up somewhere in between. Doctors can often tailor aspects of the treatment plan to suit a patient’s needs, especially for those who don’t live near a dedicated cancer center. Patients unable to travel or find temporary housing might touch base occasionally with a specialist like Gralow but receive the majority of their care from their hometown doctor.
When specialization counts
Although cancer patients of all stripes can potentially benefit from a second opinion, experts say there’s one group who should especially consider seeking them out – those with uncommon cancers.
Dr. Seth Pollack is a clinical researcher at Fred Hutch and treats patients at SCCA with sarcomas, a relatively rare group of cancers that arise from connective tissues such as bone, fat or muscle. Sarcomas make up only 1 percent of all cancer cases in the U.S., but there are 70 diverse types.
Patients with a sarcoma of the bone, for example, may need a vastly different type of treatment than a patient with a muscle sarcoma, Pollack said. And this is where treatment, or at least guidance, from a sarcoma expert may be key.
“One thing that can be really frustrating for patients who don’t see a sarcoma specialist is that their doctor may not have taken care of a patient with their exact kind of sarcoma before,” Pollack said. “For those patients, I think it can be really helpful to see a doctor who’s very familiar with their cancer type and has treated a lot of different patients with that cancer, enough to have seen some things that work and don’t work.”
Sometimes oncologists’ specialization pays off in tangible ways, as Gadi, the breast cancer oncologist, recounts. Two years ago, he met a woman with breast cancer at an event and knew at first glance that something was off.
“It’s one of those things, you look at somebody and realize she’s not getting optimum care,” Gadi said. “I just had a gut feeling. The way somebody moves, the way their hands and face look, their energy levels – good physicians start paying attention to those things.”
It turned out he was right. By coincidence, the woman came to Gadi’s clinic at SCCA for a second opinion just a few weeks later, looking for what she thought was a last-ditch effort. Gadi and his team ended up completely changing her care and she’s now doing very well. The regimen that Gadi prescribed was based on the most recent data in the field.
“There was a lot more available to her that her last physician wasn’t aware of … When you’re a specialist, you have your ear to the ground of what’s coming out,” Gadi said. “We have the liberty and the opportunity to be very focused.”
Solid tumors, such as sarcomas and those of the breast, are the focus of Solid Tumor Translational Research, a network comprised of Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Cancer Care Alliance. STTR is bridging laboratory sciences and patient care to provide the most precise treatment options for patients with solid tumor cancers.